AMRN vs. ORGO, FBLG, ANRO, RVNC, TERN, ACIU, KRRO, VRCA, STTK, and NBTX
Should you be buying Amarin stock or one of its competitors? The main competitors of Amarin include Organogenesis (ORGO), FibroBiologics (FBLG), Alto Neuroscience (ANRO), Revance Therapeutics (RVNC), Terns Pharmaceuticals (TERN), AC Immune (ACIU), Korro Bio (KRRO), Verrica Pharmaceuticals (VRCA), Shattuck Labs (STTK), and Nanobiotix (NBTX). These companies are all part of the "pharmaceutical preparations" industry.
Organogenesis (NASDAQ:ORGO) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation and community ranking.
Organogenesis has a net margin of 1.34% compared to Organogenesis' net margin of -18.96%. Amarin's return on equity of 2.11% beat Organogenesis' return on equity.
Amarin received 746 more outperform votes than Organogenesis when rated by MarketBeat users. Likewise, 74.45% of users gave Amarin an outperform vote while only 66.21% of users gave Organogenesis an outperform vote.
Organogenesis has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.
49.6% of Organogenesis shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 34.0% of Organogenesis shares are held by company insiders. Comparatively, 2.0% of Amarin shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Organogenesis currently has a consensus price target of $4.83, indicating a potential upside of 76.40%. Amarin has a consensus price target of $1.08, indicating a potential upside of 24.52%. Given Amarin's stronger consensus rating and higher possible upside, analysts clearly believe Organogenesis is more favorable than Amarin.
In the previous week, Organogenesis' average media sentiment score of 0.36 beat Amarin's score of 0.00 indicating that Amarin is being referred to more favorably in the news media.
Organogenesis has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Amarin has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500.
Summary
Organogenesis beats Amarin on 12 of the 17 factors compared between the two stocks.
Get Amarin News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
